Zhao et al. reported that ovarian cancer imposed glucose restriction on T cells, leading to high expression of microRNAs miR-101 and miR26a, leading to constrained expression Ezh2. Ezh2 is a suppressor of Notch pathway inhibitors Numb and Fbxw7. As a consequence, the cancer-induced glucose restriction led to the suppression of the Notch pathway. Here, EZH2 is linked to ovarian carcinoma.